Seaport Therapeutics, GlyphAgo, SPT-320, Glyph Agomelatine, Phase 2a, Generalized Anxiety Disorder, GAD, Sleep Disturbance, Neuropsychiatry, Anxiety, Agomelatine,

BOSTON — October 7, 2026 Seaport Therapeutics announced that the first patient has been dosed in a Phase 2a...